Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MGD-024
- Development stage
- Phase 1
- Lead developer
- MacroGenics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
MGD-024 is an investigational, next-generation bispecific DART (Dual-Affinity Re-Targeting) molecule that targets both CD123 and CD3. It is designed to engage CD3 on immune effector cells (such as T cells) and redirect them to kill cancer cells expressing CD123, a marker found on various hematological malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The molecule was engineered to minimize cytokine-release syndrome while maintaining anti-tumor cytolytic activity and allowing for intermittent dosing due to its longer half-life. Its mechanism of action includes antibody-dependent cell-mediated cytotoxicity (ADCC) and T lymphocyte stimulation[1][2][4][5][9].
- Other names
- anti-CD123/anti-CD3 bispecific DART molecule
02
Targets
CD3 (T-cell surface glycoprotein CD3)IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on MGD-024.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MGD-024.